Coordinatore | FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA
Organization address
address: CARRER ROSSELLO 149-153 contact info |
Nazionalità Coordinatore | Spain [ES] |
Totale costo | 3˙676˙199 € |
EC contributo | 2˙828˙458 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2012-INNOVATION-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-09-01 - 2015-11-30 |
# | ||||
---|---|---|---|---|
1 |
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA
Organization address
address: CARRER ROSSELLO 149-153 contact info |
ES (BARCELONA) | coordinator | 525˙600.00 |
2 |
ODENSE UNIVERSITETSHOSPITAL
Organization address
address: Sdr. Boulevard 29 contact info |
DK (ODENSE) | participant | 361˙172.00 |
3 |
UNIVERSITA CATTOLICA DEL SACRO CUORE
Organization address
address: Largo Agostino Gemelli 1 contact info |
IT (MILANO) | participant | 347˙120.00 |
4 |
LUDWIG BOLTZMANN GESELLSCHAFT GMBH
Organization address
address: NUSSDORFER STRASSE 64 6 STOCK contact info |
AT (WIEN) | participant | 297˙120.00 |
5 |
UNIVERSIDAD DE NAVARRA
Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL contact info |
ES (PAMPLONA) | participant | 277˙119.00 |
6 |
NASJONALT KUNNSKAPSSENTER FOR HELSETJENESTEN
Organization address
address: ST OLAVSPLASS 2 contact info |
NO (OSLO) | participant | 240˙120.00 |
7 |
Nome Ente NON disponibile
Organization address
address: STENBACKINKATU 9 contact info |
FI (HELSINKI) | participant | 238˙848.00 |
8 |
HOSPICES CANTONAUX CHUV
Organization address
address: Rue du Bugnon 21 contact info |
CH (LAUSANNE) | participant | 187˙119.00 |
9 |
Ministry of Health
Organization address
address: Mithatpasa Cad. 3 contact info |
TR (Sihhiye Ankara) | participant | 177˙120.00 |
10 |
SIHTASUTUS TARTU UELIKOOLI KLIINIKUM
Organization address
address: PUUSEPA 1A contact info |
EE (TARTU) | participant | 177˙120.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
The use of HTA as a part of the decision-making process at national, regional, and international levels has evolved considerably over the past 35 years. However, still an important number of good-value innovative HTs never reach clinical practice while, in many instances, others with no significant added value actually do. This situation can be effectively overcome by approaching HTA at hospital level, notably because hospitals are the main entry level for innovative HTs. To address these challenges, the AdHopHTA project aims at strengthening the use and impact of quality HTA results in hospital settings, making available pragmatic knowledge and tools to boost adoption of hospital based HTA initiatives. The project also aims at creating an adequate ecosystem where formal coordination among existing hospital based HTA initiatives and liaison with national and regional agencies will flourish. AdHopHTA focuses on hospital based HTA, an area not previously addressed by EUnetHTA, and in need of greater attention due to the considerable volume of resources that hospitals mobilise around investments in HTs. Through the 7 work packages, AdHopHTA will achieve the following 4 strategic objectives: 1) To perform a critical analysis of current formally established hospital based HTA initiatives; 2) To provide with a set of principles for best practice in hospital based HTA; 3) To advance a framework for setting a collaboration among current hospital based HTA initiatives and deployment to other interested EU hospitals; and, 4) To promote the collaboration and coordination of hospital HTA initiatives with HTA National/Regional organisations. The final results of AdhoptHTA will be: a) development of guiding principles on best practices for hospital based HTA; b) an accompanying toolkit to facilitate the deployment of such principles; c) the design and set-up of a database for hospital based HTA products in coordination/compatibility with the POP database (EUnetHTA)
Technology has the potential to improve clinical practice. An EU-funded project is exploring how to ensure that only high-value innovations are implemented.
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors
Read MoreAsian Regional Capacity Development for Research on Social Determinants of Health
Read MoreSupporting the Use of Research Evidence (SURE) for Policy in African Health Systems
Read More